Gretchen Benson1, Dawn R Witt2, Jeffrey J VanWormer3, Susan M Campbell4, Arthur Sillah5, Sharonne N Hayes6, Matt Lui2, Martha Gulati7. 1. Population Health, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. Electronic address: gbenson@mhif.org. 2. Population Health, Minneapolis Heart Institute Foundation, Minneapolis, MN, USA. 3. Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Foundation, Marshfield, WI, USA. 4. WomenHeart, Washington, DC, USA. 5. Division of Applied Research, Allina Health, Minneapolis, MN, USA. 6. Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA. 7. Division of Cardiology, University of Arizona, Phoenix, AZ, USA.
Abstract
BACKGROUND: Hypercholesterolemia is a major risk factor for cardiovascular disease. Women with hypercholesterolemia and familial hypercholesterolemia (FH) are a high-risk group often underdiagnosed, undertreated, and unaware of the need for cascade screening. OBJECTIVES: The objectives were to identify the prevalence of hypercholesterolemia and FH in 2 national databases, explore lifestyle/medication adherence, and examine rates of cascade screening (lipid testing in all first-degree relatives) among those with FH. METHODS: This was a cross-sectional study of women who completed an online survey in 2014. Outcomes were examined for 3 groups: diagnosed, probable, and no FH. For FH, multivariable logistic regression was used to examine the association between family member screening for FH and sociodemographic and/or clinical characteristics. RESULTS: There were 761 respondents with a mean (±standard deviation) age of 59 ± 10.1 years; 26% reported FH, 22% probable FH, and 51% no FH. Eighty-three percent of the total sample and 95% with FH take a statin. In those with hypercholesterolemia and FH, 65% and 58% reported high medication adherence, respectively. Women with probable FH consumed significantly fewer fruits/vegetables and were less active. FH cascade screening was: siblings 54%, parents 37%, and children 34%. Marital status, annual household income, and diabetes were significantly associated with cascade screening. CONCLUSION: In a survey of informed women with hypercholesterolemia and FH, cascade screening is underused. Our findings warrant increased efforts to identify cascade screening barriers. Early detection and treatment of hypercholesterolemia/FH is a priority for women, and their first-degree relatives, as this may dramatically reduce cardiovascular disease impact.
BACKGROUND:Hypercholesterolemia is a major risk factor for cardiovascular disease. Women with hypercholesterolemia and familial hypercholesterolemia (FH) are a high-risk group often underdiagnosed, undertreated, and unaware of the need for cascade screening. OBJECTIVES: The objectives were to identify the prevalence of hypercholesterolemia and FH in 2 national databases, explore lifestyle/medication adherence, and examine rates of cascade screening (lipid testing in all first-degree relatives) among those with FH. METHODS: This was a cross-sectional study of women who completed an online survey in 2014. Outcomes were examined for 3 groups: diagnosed, probable, and no FH. For FH, multivariable logistic regression was used to examine the association between family member screening for FH and sociodemographic and/or clinical characteristics. RESULTS: There were 761 respondents with a mean (±standard deviation) age of 59 ± 10.1 years; 26% reported FH, 22% probable FH, and 51% no FH. Eighty-three percent of the total sample and 95% with FH take a statin. In those with hypercholesterolemia and FH, 65% and 58% reported high medication adherence, respectively. Women with probable FH consumed significantly fewer fruits/vegetables and were less active. FH cascade screening was: siblings 54%, parents 37%, and children 34%. Marital status, annual household income, and diabetes were significantly associated with cascade screening. CONCLUSION: In a survey of informed women with hypercholesterolemia and FH, cascade screening is underused. Our findings warrant increased efforts to identify cascade screening barriers. Early detection and treatment of hypercholesterolemia/FH is a priority for women, and their first-degree relatives, as this may dramatically reduce cardiovascular disease impact.
Authors: Swetha Srinivasan; Nae Yeon Won; W David Dotson; Sarah T Wright; Megan C Roberts Journal: Eur J Hum Genet Date: 2020-09-18 Impact factor: 4.246
Authors: Karen Forrest Keenan; Robert M Finnie; William G Simpson; Lorna McKee; John Dean; Zosia Miedzybrodzka Journal: J Community Genet Date: 2018-06-14
Authors: Gemme Campbell-Salome; Nicole L Walters; Ilene G Ladd; Amanda Sheldon; Catherine Davis Ahmed; Andrew Brangan; Megan N McMinn; Alanna K Rahm; Marci L B Schwartz; Eric Tricou; Carla L Fisher; Amy C Sturm Journal: Transl Behav Med Date: 2022-07-18 Impact factor: 3.626